louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05823181: Early Versus Late Laparoscopic Exploration of Common Bile Duct After Failure of Extraction of Common Bile Duct Stones by ERCP
Official title: Early Versus Late Laparoscopic Exploration of Common Bile Duct After Failure of Extraction of Common Bile Duct Stones by ERCP
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Common Bile Duct Calculi
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2023-04-21
Enrollment: 50
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients that presented with calcular obstructive jaundice 2ry to CBD stones and failed of extraction of common bile duct stone by ERCP.

Brief summary: The goal of this work is to assess the best time to perform LC combined with LCBD exploration and the feasibility and safety of such procedure in patients with combined GBS and CBDS after failure of ERCP extraction of CBD stones .


Eligibility criteria: Inclusion Criteria:

1. All patients that presented with calcular obstructive jaundice 2ry to CBD stones.
2. Failed of extraction of common bile duct stone by ERCP.

Exclusion Criteria:

1. patients presented by cholangitis.
2. patients presented by acute pancreatitis.
3. Patients that developed post ERCP pancreatitis ,bleeding , perforation.
4. history of previous biliary surgery rather than cholecystectomy.
5. history of major upper abdominal surgery.
6. pregnant females.
7. patients with liverchirosis, abdominal malignancy , and those unfit for surgery.

Primary outcomes:
measure: intraoperative complications
timeFrame: Baseline
Secondary outcomes:
measure: postoperative complications
timeFrame: Baseline
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00253981: Light Therapy in the Treatment of Leg Pain
Official title: Monochromatic Near-Infrared Light Energy (MIRE) in the Treatment of Tibial Stress Reaction
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Tibial Fractures
Leg Injuries
Keywords: Pain, Intractable
Infrared Rays
Leg
Lead sponsor: Samueli Institute for Information Biology
Sponsor class: OTHER
Collaborators: name: William Beaumont Army Medical Center
First posted: 2005-11-15
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to apply Anodyne therapy to active duty soldiers, who have shin splints, to evaluate healing time and effectiveness.

Detailed description: Tibial stress reactions and fractures are often difficult to treat, and therefore, many soldiers proceed to a medical disability/discharge. It is felt that with the use of the MIRE technology, active duty soldiers with tibial stress reactions and fractures will heal more quickly and completely. All soldiers will have a documented bone scintigraph as evidence for tibial stress reaction or fracture prior to enrollment. In addition, pain-pressure goniometric measures and time to complete the Balke protocol will also be used to assess healing with the MIRE technology.

Comparison: Soldiers with Active MIRE technology, compared to soldiers with Placebo MIRE technology.

Eligibility criteria: Inclusion Criteria:

* Active duty soldier
* Exertional leg pain of greater than 3 months duration
* Documented bone scintigraphic evidence for tibial stress reaction or fracture

Exclusion Criteria:

* Known leg Pathology other than stress reaction or fracture
* Service members known to be leaving area within next 6 months
* Pregnant females
* High risk cardiopulmonary patients
* Patients with assisted walking devices
* Patients with two or more cardiac risk factors

Primary outcomes:
measure: Visual Analog Scale
timeFrame: 4 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: El Paso
country: United States
facility: William Beaumont Army Medical Center
state: Texas
Study officials:
affiliation: Department of the Army
name: LTC Richard P Petri, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06953895: The Immediate Effect of Mulligan's Mobilization With Movement on Shoulder Girdle' Pain, Range of Motion and Muscle Activity, in Subjects With Shoulder Impingement Syndrome
Official title: The Immediate Effect of Mulligan's Mobilization With Movement on Shoulder Girdle' Pain, Range of Motion and Muscle Activity, in Subjects With Shoulder Impingement Syndrome
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Shoulder Impingement Syndrome
Keywords: Subacromial impingement syndrome
Mobilization with movement
Pressure pain threshold
Surface electromyography
Lead sponsor: Escola Superior de Tecnologia da Saúde do Porto
Sponsor class: OTHER
First posted: 2025-05-01
Enrollment: 24
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of present study was to evaluate the immediate effect of Mulligan's mobilization with movement on shoulder girdle' pain, range of motion (ROM) and muscle activity, in subjects with shoulder impingement syndrome

Detailed description: A randomized, single-blind, placebo-controlled clinical trial was conducted with a sample composed by twenty-four volunteers with SIS, divided in Mulligan's MWM and Placebo groups. Pain intensity in Neer impingement signal and Hawkins-Kennedy impingement test, pressure pain threshold (PPT) on the lateral aspect of shoulder, ROM of shoulder scaption until onset of pain, as well as the activity of trapezius (upper, middle and lower fibers) and serratus anterior muscles during this movement, were evaluated before and immediate (post-) intervention. The Mulligan's MWM group received a mobilization with movement technique in the glenohumeral joint (sustained posterolateral glide during shoulder scaption), while no effective intervention was performed in the Placebo group.

Eligibility criteria: Inclusion Criteria:

Participants had superolateral shoulder pain and two out of four specified objective signs and symptoms:

* positive Neer test;
* positive Hawkins-Kennedy test;
* painful limitation of active arm elevation (flexion, abduction, scaption);
* pain or limitation with functional movement patterns of hand behind back or hand behind head.

Exclusion Criteria:

* physician diagnosis of adhesive capsulitis;
* grade III rotator cuff tear;
* calcific tendinosis confirmed by radiology;
* systemic or neurological disorder;
* cervical radiculopathy; a history of shoulder surgery;
* corticosteroid injection within the past month;
* subjects who had received physical therapy intervention for their shoulder within the past three months.

Primary outcomes:
measure: Pain intensity
timeFrame: baseline
measure: Pain Pressure Threshold on the lateral aspect of shoulder
timeFrame: baseline
measure: Shoulder ROM
timeFrame: baseline
measure: Shoulder muscle activity
timeFrame: baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Porto
country: Portugal
facility: E2S | P.PORTO - Escola Superior de Saúde do Politécnico do Porto
Study officials:
References:
Clinical trial NCT04794595: Clinical Features and Outcomes of CBP Versus Non-CBP in Septic Children
Official title: Clinical Features and Outcomes of Continuous Blood Purification Versus Non-continuous Blood Purification in Pediatric Patients With Sepsis or Septic Shock
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Sepsis
Children, Only
Keywords: Continuous renal replacement therapy
sepsis
timing
Lead sponsor: Children's Hospital of Fudan University
Sponsor class: OTHER
Collaborators: name: Shanghai Children's Hospital
name: Shanghai Children's Medical Center
name: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
First posted: 2021-03-12
Enrollment: 90
Sex: ALL
Minimum age (years): 28
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: children with sepsis requiring blood purification to prevent or treat fluid overload or to clear cytokines

Brief summary: The effect of continuous blood purification (CBP) in children is unclear. Also, the timing of early application is still being explored. In this study, we need to explore the efficacy and the timing of application of CBP in children with sepsis or septic shock.

Detailed description: Early intervention of CBP can remove inflammatory factors in patients with sepsis and reduce the damage of inflammatory factors to organs; at the same time, it can also promote the body's immune response, significantly improve immune dysfunction, and restore the body's immune balance. However, the timing of early application of CBP in childhood sepsis is still unclear. Therefore, it is necessary to further explore the treatment and prognosis of this technology in the early treatment of sepsis.

Eligibility criteria: Inclusion Criteria:

* Age of 29d to 18 years old;
* Children diagnosed with sepsis requiring blood purification.

Exclusion Criteria:

* with a history of a duration of PICU stay \<24 h
* active bleeding, including cerebral hemorrhage

Primary outcomes:
measure: survival rate
timeFrame: 28 days after hospital discharge
Secondary outcomes:
measure: The creatinine level of non-survival children with sepsis
timeFrame: 28 days after hospital discharge
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Children'S Hospital of Fudan University
state: Shanghai
Study officials:
affiliation: Children's Hospital of Fudan University
name: Lu guoing
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03296995: Accuracy, Feasibility and Acceptance of CGM Lupus
Official title: Accuracy, Feasibility and Acceptance of Continuous Glucose Monitoring in Critically Systemic Lupus Erythematosus
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Systemic Lupus Erythematosus
Critical Illness
Diabetic Blood Glucose Monitoring
Keywords: glucose
systemic lupus erythematosus
Lead sponsor: RenJi Hospital
Sponsor class: OTHER
First posted: 2017-09-29
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SCREENING

Brief summary: This is a prospective monocenter, non-randomised, open-lable single-group intervention diagnostic trial on the accuracy, reliability and feasibility of the continuous glucose monitoring system in critically systemic lupus erythematosus (SLE). Newly developed technologies for continuous glucose monitoring in critically SLE patients may improve glycemic control and reduce glucose variability. Critically SLE patients will be performed by continuous glucose monitoring. The subcutaneous glucose will be continuously monitored in critical SLE patients by freestyle libre glucose monitoring system for 14 days. The aim of this study is to evaluate accuracy feasibility and acceptance of these methods. To analyze accuracy sensor glucose levels will be validated due to venous blood measurements with glucose oxidase methods. The influence of several factors like oedema, perspiration, BMI, body temperature, pH-value application of vasoconstrictors on accuracy and feasibility of the particular system would be evaluated. Furthermore the acceptance of physicians and Nursing staff would be evaluated by a questionnaire.


Eligibility criteria: Inclusion Criteria:

* Systemic lupus erythematosus (SLE), as defined by meeting at least 4 of 11 classification criteria of American College of Rheumatology for the classification of systemic lupus erythematosus, either sequentially or coincidentally. The 4 criteria doesn't need to be present at the time of study enrollment;
* critically SLE patients
* informed consent by the patients or legal proxy

Exclusion Criteria:

* age \< 18
* no informed consent by the patients or legal proxy
* pregnancy
* infaust prognosis

Primary outcomes:
measure: Accuracy of continuous glucose monitoring compared to glucose oxidase method
timeFrame: 7 d
Secondary outcomes:
measure: Feasibility of continuous glucose monitoring
timeFrame: 7 d
measure: Acceptance of continuous glucose monitoring by physicians and nursing staff
timeFrame: 7 d
Other outcomes:
measure: Technical problems with the monitoring
timeFrame: 7 d
Locations:
city: Shanghai
country: China
facility: Shuang Ye, MD
state: Shanghai
Study officials:
References:
Clinical trial NCT04567095: A Study to Evaluate Awareness and Knowledge of the Fibristal Additional Risk Minimization Measures Among Patients in Canada
Official title: A Cross-sectional Study Among Patients in Canada to Assess Awareness and Knowledge of the Fibristal Patient Alert Card
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Uterine Fibroids
Lead sponsor: Allergan
Sponsor class: INDUSTRY
First posted: 2020-09-28
Enrollment: 0
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The survey will endeavor to collect 150 completed patient surveys

Brief summary: This is a non-interventional, cross-sectional survey study to evaluate the effectiveness of the Additional Risk Minimization Measures for Fibristal among Patients in Canada.

Detailed description: Data will be collected via web-based data capture and paper surveys depending on patient preference. The survey will be conducted in a single wave over 6 months. All data will be maintained in compliance with local regulations.

Eligibility criteria: Inclusion Criteria:

* Patients who have received Fibristal within 6 months of completing the survey.
* Patients who have provided permission to share their responses in aggregate with Health Canada.
* Patients who have provided informed consent for their participation in the survey.

Exclusion Criteria:

* Patients who participated in the cognitive pre-testing of the survey questionnaire to be used for the study.
* Patients who have been direct employees of Allergan, ICON, Health Canada, or Professional Targeted Marketing (PTM) within the past year.

Primary outcomes:
measure: Percentages of patients with correct responses to the knowledge related questions based on the contents of the Fibristal Patient Alert Card.
timeFrame: 18 - 24 months
Secondary outcomes:
measure: Percentages of patients that recall recieving and using the Fibristal Patient Alert Card
timeFrame: 18 - 24 months
measure: Percentage of patients that recall their HCPs' ordering of required liver function tests in accordance with the recommendations in the aRMM/CPM
timeFrame: 18 - 24 months
Other outcomes:
Locations:
city: Irvine
country: United States
facility: Clinical Trials Registry Team
state: California
Study officials:
affiliation: Allergan
name: Ahunna Ukah
role: STUDY_DIRECTOR
References:
Clinical trial NCT05466981: HCV-Smoking Cessation Study
Official title: Smoking Cessation Intervention for Persons Infected With Hepatitis C Virus
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hepatitis C
Smoking Cessation
Lead sponsor: Prisma Health-Upstate
Sponsor class: OTHER
First posted: 2022-07-20
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: We conducted a single-arm pilot study in order to test the feasibility and preliminary efficacy of a smoking cessation intervention for people with HCV while they received standard of care treatment: antiviral medication and provider/laboratory visits.
Primary purpose: TREATMENT

Brief summary: A 12-week study for patients who are being treated for Hepatitis C and would like to quit smoking. During the 12 weeks of Hepatitis C treatment, the research team will have counseling sessions with the participants to discuss challenges related to Hepatitis C and smoking.

Detailed description: A 12-week smoking cessation intervention addressing concurrently HCV and smoking cessation The Standard of care for HCV is 12 weeks of oral medication with 3 in-person provider/laboratory visits throughout. This study utilizes both in-person and phone counseling and health education sessions. Each session will address a different topic related to HCV, smoking, and how both smoking and HCV affect health and quality of life.

Eligibility criteria: Inclusion Criteria:

* Adults (≥18 years old)
* Current HCV infection (HCV RNA+)
* Current cigarette smoking
* Patients in contemplation / preparation stage of change

Exclusion Criteria:

* Inability to speak/read English, as materials will be provided in English
* Current suicidal ideation as determined by the PHQ-9, requiring a greater level of clinical care
* Severe medical or psychiatric disability that prevents participant from ability to comprehend or consent to study

Primary outcomes:
measure: Change in the number of cigarettes smoked per day (CPD)
timeFrame: baseline (week 0) to end of treatment (week 12)
measure: Change in Fagerstrom Test for Nicotine Dependence (FTND) score
timeFrame: baseline (week 0) to end of treatment (week 12)
Secondary outcomes:
measure: Change in depressive symptomology using Patient Health Questionnaire (PHQ-9) score
timeFrame: baseline (week 0) to end of treatment (week 12)
measure: Number of quit attempts
timeFrame: baseline (week 0) to end of treatment (week 12)
Other outcomes:
Locations:
city: Greenville
country: United States
facility: Prisma Health Internal Medicine Clinic
state: South Carolina
Study officials:
affiliation: Prisma Health
name: Irene Pericot-Valverde, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Prisma Health
name: Alain Litwin, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT03227081: Behavioral Modulation of Intrusive Memories
Official title: Behavioral Modulation of Memory Traces: Influence of Sleep on Emotional Regulation and the Consolidation of Intrusive Memories
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Intrusive Memories
Lead sponsor: Charite University, Berlin, Germany
Sponsor class: OTHER
First posted: 2017-07-24
Enrollment: 101
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of the study is to examine whether sleep affects the development of intrusive memories.


Eligibility criteria: Inclusion Criteria:

* healthy participants
* German on a native level

Exclusion Criteria:

* former or present psychiatric disorders
* physical illnesses
* history of trauma
* pregnancy or lactation period

Primary outcomes:
measure: Intrusive memories
timeFrame: seven consecutive days
Secondary outcomes:
Other outcomes:
Locations:
city: Berlin
country: Germany
facility: Dr. Dimitris Repantis
Study officials:
References:
Clinical trial NCT01713881: Effect of a Tracking Program on Colon Adenoma Surveillance and Adherence to Guideline Recommendations
Official title: Effect of a Tracking Program on Colon Adenoma Surveillance and Adherence to Guideline Recommendations
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Colon Polyp Surveillance
Keywords: Polyp
colonoscopy
surveillance
Lead sponsor: United States Department of Defense
Sponsor class: FED
First posted: 2012-10-25
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with colon polyps

Brief summary: This will be a retrospective chart review of 880-1000 patients who had a colonoscopy and were found to have a tubular adenoma between the years of 2004-2008. We will compare the rate and timing of completion of repeat colonoscopies pre and post establishment of a polyp registry (tracking system) in 2006. Each group will be composed of up to 500 subjects consecutively identified from all the patients who underwent colonoscopy and were found to have a tubular adenoma (Group 1-2004 to 2006, Group 2 2007-2008).

Detailed description: This will be a retrospective chart review of 880-1000 patients who had a colonoscopy and were found to have a tubular adenoma between the years of 2004-2008. We will compare the rate and timing of completion of repeat colonoscopies pre and post establishment of a polyp registry (tracking system) in 2006. Each group will be composed of 380-500 subjects consecutively identified from all the patients who underwent colonoscopy and were found to have a tubular adenoma (Group 1-2004 to 2006, Group 2 2007-2008).

Eligibility criteria: Inclusion Criteria:

* Any adenoma found on screening/surveillance colonoscopy (ICD9-211.3, Procedure code 45385 or 45380)
* Greater than 18 years old

Exclusion Criteria:

* Less than 18 years old
* Diagnosis of IBD

Primary outcomes:
measure: Percentage completing follow up colonoscopy
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Fort Gordon
country: United States
facility: D.D. Eisenhower Army Medical Center
state: Georgia
Study officials:
References:
Clinical trial NCT06946381: CAMpania PugliA bRanch Iliaco
Official title: CAMpania PugliA bRanch Iliaco
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Aortoiliac Aneurysm
Iliac Aneurysm
Keywords: evar
bevar
AAA
Lead sponsor: Federico II University
Sponsor class: OTHER
Collaborators: name: University of Bari
First posted: 2025-04-27
Enrollment: 200
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients feferred to the insitution

Brief summary: Spontaneus Multicentric Observational registry to investigate the medium and long-term performances of the Iliac E-liac Branch Device from Artivion for treatment of Aortoiliac aneurysms in a real-world consecutive patients cohort.


Eligibility criteria: Inclusion Criteria:

* An aortoiliac or aortic aneurysm of surgical interest based on the most recent local guidelines treated with the E-liac stent-graft system, alone or in combination with other devices

Exclusion Criteria:

* Patient's refusal to be enrolled in the registry
* Patient treated with devices not including the E-liac stent-graft system

Primary outcomes:
measure: Aneurysm related death
timeFrame: assessed after procedure at 30 days, 6 months, one year, two years, three years, four years, five years.
measure: Procedure-related re intervention
timeFrame: assessed after procedure at 30 days, 6 months, one year, two years, three years, four years, five years
Secondary outcomes:
measure: Aneurysm sac dynamics
timeFrame: assessed after procedure at 30 days, 6 months, one year, two years, three years, four years, five years
Other outcomes:
Locations:
city: Bari
country: Italy
facility: Azienda ospedaliero-universitaria consorziale policlinico di Bari
state: BA
city: Naples
country: Italy
facility: Azienda Ospedaliera Universitaria Federico II
Study officials:
References: